Rashed Al Banna
Overview
Explore the profile of Rashed Al Banna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sridharan K, Kumar D T, Manikandan S, Prasanna G, Guruswamy L, Al Banna R, et al.
Curr Drug Metab
. 2023 Jul;
24(6):466-476.
PMID: 37409551
Aim: The study aimed to identify the key pharmacogenetic variable influencing the therapeutic outcomes of warfarin using machine learning algorithms and bioinformatics tools. Background: Warfarin, a commonly used anticoagulant drug,...
2.
Sridharan K, Ramanathan M, Al Banna R
Int J Clin Pharm
. 2022 Oct;
45(1):79-87.
PMID: 36306062
Background: Machine learning algorithms (MLAs) carry a huge potential in identifying predicting factors and are being explored for their utility in the field of personalized medicine. Aim: We aimed to...
3.
Sridharan K, Al Banna R, Husain A
Curr Drug Saf
. 2022 May;
18(1):23-30.
PMID: 35507798
Aims: To identify the extent and associated factors for patients with prolonged prothrombin time, international normalized ratio (PT-INR), and the dosage modifications were carried out with warfarin. Background: Studies evaluating...
4.
Sridharan K, Al Banna R, Husain A
ADMET DMPK
. 2022 Mar;
9(2):143-149.
PMID: 35299771
Background: Pharmacokinetics of warfarin has not been described in our population. We derived the pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: Patients receiving warfarin for at least 6 months...
5.
Sridharan K, Al Banna R, Husain A
Eur J Hosp Pharm
. 2021 Apr;
30(1):41-45.
PMID: 33903173
Background: The literature regarding the seasonal variation in the therapeutic response to warfarin is somewhat contradictory, with several discrepancies. We assessed the influence of seasons on various pharmacodynamic indices of...
6.
Sridharan K, Al Banna R, Malalla Z, Husain A, Sater M, Jassim G, et al.
Pharmacol Rep
. 2021 Apr;
73(5):1405-1417.
PMID: 33811620
Background: Warfarin is the most commonly evaluated drug in pharmacogenetic-guided dosing studies. However, gaps remain regarding the influence of the genetic polymorphisms of CYP2C9, VKORC1, and CYP4F2 on specific pharmacodynamic...
7.
Sridharan K, Al Banna R, Qader A, Husain A
J Clin Pharm Ther
. 2020 Sep;
46(1):86-92.
PMID: 32926452
What Is Known And Objectives: The changes in the therapeutic effect of warfarin during Ramadan fasting are controversial. Hence, we carried out the present study to assess if there are...
8.
Sridharan K, Al Banna R, Qader A, Husain A
Expert Rev Cardiovasc Ther
. 2020 Aug;
18(11):835-840.
PMID: 32820971
Objectives: Warfarin exhibits huge inter-individual variability in therapeutic response. We assessed the extent and the factors affecting inter-individual variability in the anticoagulation control using pre-validated pharmacodynamic indices. Methods: Patients receiving...
9.
Zubaid M, Rashed W, Ridha M, Bazargani N, Hamad A, Al Banna R, et al.
Angiology
. 2020 Feb;
71(5):431-437.
PMID: 32066246
We describe the characteristics of ambulatory patients with heart failure with reduced ejection fraction (HFrEF) in the Gulf region (Middle East) and the implementation of guideline-recommended treatments. We included 2427...
10.
Al Banna R, Husain A, Al-Ghamdi B
BMJ Case Rep
. 2019 Dec;
12(12).
PMID: 31843774
Gitelman syndrome (GS) is an autosomal recessive tubulopathy recently implicated in cases with ventricular arrhythmias (VAs), the latter being considered linked to electrolytes' imbalance. However, a direct causal relationship is...